Trial Condition(s):

Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS)

Portuguese observational survey to assess drug adherence in patients with multiple sclerosis after conversion to Betaferon by using elements of the BetaPlus program - nurse support, auto-injectors (POR-BetaPlus)

Bayer Identifier:

14235

ClinicalTrials.gov Identifier:

NCT01235455

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors. The patients were evaluated under normal clinical practice and were asked to fill out the quality of life FAMS questionnaire, Coping processes (WCQ) and depression questionnaire CES-D.

Inclusion Criteria
- Relapsing-remitting MS (RRMS) or secondary-progressive MS (SPMS)
 - Previous treatment with disease modifying drugs
 - Adjustment of disease modifying treatment necessary at the discretion of the investigator
 - Switch to Betaferon at least 1 month but not longer than 3 months prior to inclusion
Exclusion Criteria
- Patients not fulfilling the indications in the local prescribing information
 - Refusal to sign inform consent

Trial Summary

Enrollment Goal
10
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Portugal

Status
Completed
 

Trial Design